ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing

Thermo Fisher Scientific opens cell therapy facility at University of California

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

USFDA approves Novartis Kymriah CAR-T cell therapy

68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile

SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer

SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer

Global Cord Blood Corp acquires Cellenkos to advance cell therapy market

CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products

Porton Advanced and Sinorda Biomedicine collaborate for cell therapy development for solid tumours

Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine

USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma

Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --

DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection